Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS: Eligible patients with ECOG PS 0–1 were treated with eribulin-LF either on day 1 every 21 days...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461749/
https://www.ncbi.nlm.nih.gov/pubmed/30679780
http://dx.doi.org/10.1038/s41416-019-0377-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461749/
https://www.ncbi.nlm.nih.gov/pubmed/30679780
http://dx.doi.org/10.1038/s41416-019-0377-x

Ejemplares similares